Edition:
United States

Halozyme Therapeutics Inc (HALO.O)

HALO.O on Nasdaq

12.95USD
3:21pm EDT
Change (% chg)

$-1.34 (-9.38%)
Prev Close
$14.29
Open
$12.90
Day's High
$13.29
Day's Low
$12.44
Volume
5,454,068
Avg. Vol
1,719,582
52-wk High
$15.20
52-wk Low
$7.70

Latest Key Developments (Source: Significant Developments)

Halozyme Therapeutics Q4 loss per share $0.21
Tuesday, 28 Feb 2017 04:05pm EST 

Halozyme Therapeutics Inc : Says for 2017, company reiterated and updated cash portions of its financial guidance . Sees 2017 operating expenses of $240 million to $250 million . Sees 2017 operating cash burn of $75 million to $85 million . FY2017 revenue view $131.6 million -- Thomson Reuters I/B/E/S . Halozyme reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.21 . Q4 revenue $39 million versus I/B/E/S view $38.4 million . Q4 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S .Sees FY 2017 revenue $115 million to $130 million.  Full Article

First Eagle Investment Management LLC reports a 5.94 pct passive stake in Halozyme Therapeutics as of Dec 31 - SEC Filing
Monday, 6 Feb 2017 05:02pm EST 

Halozyme Therapeutics Inc :First Eagle Investment Management LLC reports a 5.94 percent passive stake in Halozyme Therapeutics Inc as of December 31, 2016 - SEC Filing.  Full Article

Halozyme Therapeutics sees FY 2017 revenue $115 mln to $130 mln
Monday, 9 Jan 2017 04:05pm EST 

Halozyme Therapeutics Inc : Halozyme Therapeutics-expects to report $20 million in 2016 revenue for reimbursed partner research and development expenses . Halozyme provides program updates, 2017 financial guidance at 35th annual JP Morgan healthcare conference . Sees FY 2017 revenue $115 million to $130 million .Company expects to report $20 million in 2016 revenue for reimbursed partner research and development expenses that will not recur in 2017.  Full Article

Halozyme provides update on Abbvie collaboration
Monday, 21 Nov 2016 08:30am EST 

Halozyme Therapeutics Inc : Halozyme Therapeutics Inc - abbvie has discontinued a development program using halozyme enhanze platform technology . Halozyme - co, abbvie will continue to work to identify additional targets for co-development under 2015 global collaboration,licensing agreement . Halozyme Therapeutics - abbvie has discontinued development program following completion of a phase 1 study in which target results were not achieved . Halozyme Therapeutics-abbvie discontinued development program using halozyme enhanze platform technology, tnf-alpha target after completion of phase 1 study .Halozyme provides update on abbvie collaboration.  Full Article

Halozyme reports second quarter 2016 financial results
Tuesday, 9 Aug 2016 04:05pm EDT 

Halozyme Therapeutics Inc : Halozyme reports second quarter 2016 financial results . Q2 revenue $33.3 million versus I/B/E/S view $29.9 million . Sees FY 2016 revenue $140 million to $150 million . Q2 loss per share $0.21 . Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Sees 2016 operating expenses to continue to be in range of $245 million to $260 million .FY2016 revenue view $138.7 million -- Thomson Reuters I/B/E/S.  Full Article

Halozyme to resume enrollment in Phase 1B trial evaluating PEGPH20
Monday, 25 Jul 2016 09:00am EDT 

Halozyme Therapeutics Inc : Resumed enrollment, dosing patients in phase 1B trial evaluating investigational new drug, PEGPH20, in combination with KEYTRUDA . Revised protocol has been submitted to all institutional review boards (IRB) and is pending feedback from FDA .Majority of institutional review boards have completed their review and approved revised protocol allowing study to resume.  Full Article

Halozyme announces agreement to refinance debt
Wednesday, 8 Jun 2016 09:00am EDT 

Halozyme Therapeutics Inc : Entered into agreement with Oxford Finance Llc and Silicon Valley Bank to refinance its existing senior secured loan facility . Under new financing agreement, Halozyme borrowed $55 million at a fixed rate of 8.25% . New debt facility provides option to borrow additional $15 million in 2017 . Interest-Only repayment provision results in $44 million increase to expected cash balance through 2017 . Under new financing agreement, Halozyme used proceeds to refinance its existing long-term debt . Agreement will result in a $22 million per-year increase to company's expected cash balance at end of 2016 and 2017 . Expecting a year-end cash balance of $170 million to $190 million .Announces agreement to refinance debt, increases 2016 guidance for year-end cash balance.  Full Article

Halozyme Q1 loss per share $0.16
Monday, 9 May 2016 04:22pm EDT 

Halozyme Therapeutics Inc : Halozyme therapeutics inc sees 2016 net revenues to be in range of $130 million to $145 million . Halozyme therapeutics inc sees 2016 cash flow to be in range of $45 million to $65 million . Fy2016 earnings per share view $-0.98, revenue view $127.9 million -- Thomson Reuters I/B/E/S . Halozyme reports first quarter 2016 financial results . Q1 loss per share $0.16 . Q1 revenue $42.5 million versus $18.7 million . Q1 revenue view $29.7 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Inc maintains FY 2016 net revenues guidance
Monday, 29 Feb 2016 04:06pm EST 

Halozyme Therapeutics Inc:For Fy 2016, the company maintains its previously announced guidance of Net revenues to be in the range of $110 million to $125 million.  Full Article

Halozyme says closing Of $150 Million Royalty-Backed Debt Financing
Tuesday, 26 Jan 2016 04:06pm EST 

Halozyme Therapeutics Inc:Closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management.Debt is secured by future royalties of ENHANZE(tm) products, received only from Halozyme's collaborations with Roche and Baxalta.  Full Article

More From Around the Web